Delivery Order SPE2DR25D3103-SPE2DR26F9G46
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for 90 tablets of Gemtesa 75 mg with a ceiling value of $7,551.80 under a Firm Fixed Price contract structure. This is a non-set-aside competitive award with an ultimate completion date of October 30, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $1,389.38. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $6,194.63. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Gemtesa 75 mg tablets (30-count packages) with a contract ceiling value of $4,316.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,279.87 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count package) on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $7,642.01 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) with completion targeted for September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $14,891.75 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on November 6, 2025, with completion scheduled for November 7, 2025. This firm fixed-price contract is a non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00 and extends through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $3,103.31. This firm fixed-price delivery order, which is expected to be completed by November 4, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,148.50 for 90-tablet supplies of Gemtesa 75 mg tablets under a firm fixed-price contract. The award, made on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a competitively awarded, non-set-aside procurement. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $37,071.79 delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for October 30, 2025. The contract employs firm fixed pricing with no small business set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9G46Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $33,238.55. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen Drug Corp's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which enables the company to furnish a broad range of medications and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen serves critical federal medical procurement needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The pharmaceutical prime vendor model provides the flexibility to deliver specialized medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains to support defense and veteran healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.2k | 11/18/25 |